Participant flow

Allogeneic Transplantation in Patients With Cutaneous T-Cell Lymphoma · Source last updated 2020-12-29

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Fludarabine 25 mg/m\^2 intravenous (IV) daily for 5 days prior to allogeneic peripheral blood progenitor cell (PBPC) , Melphalan 70 mg/m\^2 IV daily for 2 days prior to IV Allogeneic Transplant following Fludarabine \& Melphalan. Thymoglobulin 2 mg/kg/day IV on days -3, -2 \& -1 for patients receiving matched unrelated marrow/stem cells or mismatched related marrow.

   id

   FG000

   title

   Fludarabine + Melphalan With PBPC

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         15

      type

      Disease Progression/Relapse

   2. reasons

      1. group Id

         FG000

         num Subjects

         7

      type

      Death

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         33

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         11

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         22

      type

      NOT COMPLETED

   title

   Overall Study

recruitment Details

Recruitment Period: September 26, 2003 to November 05, 2012. All recruitment done at The University of Texas MD Anderson Cancer Center.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice